Mr. Miguel Martin reports

AURORA CANNABIS AND VECTURA FERTIN PHARMA, INC. ANNOUNCE COMMERCIAL COLLABORATION

Aurora Cannabis Inc. has entered into a commercial collaboration with Cogent International Manufacturing Ltd., a wholly owned subsidiary of Vectura Fertin Pharma Inc. Through this arrangement, Cogent will initially launch its newly developed cannabidiol lozenge on Aurora's Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis. Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.

"We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma's new CBD lozenge," said Miguel Martin, chief executive officer for Aurora. "As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of health care options made available to Canadians."

Michael Kunst, chief executive officer for Vectura Fertin Pharma, said: "At Vectura Fertin Pharma, we are committed to building a pipeline of innovation, based on scientific rigour, to improve unmet medical and health needs. We are delighted to be working with the Aurora team who share our high standards for safety and quality, and our strong focus on improving people's lives. Through this strategic collaboration, the Aurora platform will enable us to bring our new CBD lozenge, as prescribed by a health care professional, to the largest patient base in Canada, and to both study its impact and validate the product proposition through the generation of real-world patient data."

Select agreement details

The agreement between Aurora and Cogent is expected to have an initial term of 24 months, with a target of launching CBD containing products on Aurora's Canadian medical cannabis marketplace, starting with a CBD lozenge. The products will be manufactured, packaged and labelled by Cogent for sale and distribution by Aurora through its leading direct-to-patient e-commerce sales channel, requiring minimal additional capital investment by Aurora. The expected launch of the first stock-keeping unit in market is targeted for later in 2024.

About Vectura Fertin Pharma

Vectura Fertin Pharma is developing and commercializing a proprietary pipeline of differentiated products and brands in wellness and health care that address unmet patient and consumer needs. The company has unique research and development capabilities in inhaled and oral technology, which it is applying across four key areas: cannabinoids, inhaled therapeutics, nicotine replacement therapy and consumer health. Underpinned by scientific rigour, and patient and consumer insights, Vectura is passionate about finding new and better ways to help people take care of their health and well-being. Vectura Fertin Pharma was formed in March, 2022, following the acquisition of Fertin Pharma, Vectura Group PLC and OtiTopic by Philip Morris International.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

Aurora's common shares trade on the NASDAQ and TSX under the symbol ACB.

We seek Safe Harbor.